{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"24.4","value":"25.5"}]}],"title":"Cycle 2, Day 1 (Pre-dose)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"20.6","value":"22.6"}]}],"title":"Cycle 3, Day 1 (Pre-dose)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"47.2","value":"47.7"}]}],"title":"Cycle 3, Day 1 (Post-dose)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"24.3","value":"25.2"}]}],"title":"Cycle 4, Day 1 (Pre-dose)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"30.6","value":"24.5"}]}],"title":"Cycle 5, Day 1 (Pre-dose)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"18.0","value":"20.9"}]}],"title":"Cycle 6, Day 1 (Pre-dose)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"373"}],"units":"Participants"}],"description":"Individual plasma primary metabolite concentrations at each sampling time","dispersionType":"Standard Deviation","groups":[{"description":"Tucatinib in combination with capecitabine \\& trastuzumab","id":"OG000","title":"Tuc+Cap+Tra"}],"paramType":"MEAN","populationDescription":"PK Analysis Set: Includes all randomized participants who received at least one dose of tucatinib and who had at least one evaluable PK assessment. Participants were evaluated by the treatment actually received.","reportingStatus":"POSTED","timeFrame":"3.5 months","title":"Pharmacokinetic Measure: ONT-993","type":"SECONDARY","unitOfMeasure":"ng/mL"}